Alvotech, Teva Sign Deal with Regeneron to Launch Eylea Biosimilar in US

06:59 AM EST, 12/19/2025 (MT Newswires) -- Alvotech (ALVO.IC) and Teva Pharmaceuticals signed a settlement and license agreement with Regeneron Pharmaceuticals for the launch of AVT06, Alvotech's proposed biosimilar to Eylea, in the US. The settlement with the US-based pharmaceutical company grants a license entry date for AVT06 in the US market in the fourth quarter of 2026 or potentially earlier, according to a Friday release. The Icelandic biotechnology company's biosimilar to Eylea, or aflibercept, is a treatment for patients with wet age-related macular degeneration.